Contact
Please use this form to send email to PR contact of this press release:
Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023
TO: